Sinocelltech(688520.SH)

Last Updated 00:00:00
longbridge loading

02:28 ETWorld-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors

prnewswire·
SH
688520
+1.31%
HK
上海细胞治疗...
0.00%
prnewswire·
SH
688520
+1.31%
HK
上海细胞治疗...
0.00%

Sinocelltech released its semi-annual performance report, with a net loss attributable to the parent company of 33.77 million yuan, turning from profit to loss year-on-year

Zhitong·
SH
688520
+1.31%
Zhitong·
SH
688520
+1.31%

Guotai Junan Securities: China's innovative drugs are in the early stage of realizing innovative achievements, optimistic about the potential emergence of the next blockbuster product in specific segments

Zhitong·
HK
01177
+2.13%
HK
01530
-1.56%
SH
688520
+1.31%
Zhitong·
HK
01177
+2.13%
HK
01530
-1.56%
SH
688520
+1.31%

Sinocelltech: SCT640C injection has received approval for clinical trials

Zhitong·
SH
688520
+1.31%
Zhitong·
SH
688520
+1.31%

Sinocelltech's subsidiary product SCT640C has received approval for clinical drug trials

Zhitong·
SH
688520
+1.31%
Zhitong·
SH
688520
+1.31%

The three major indices of A-shares in Shanghai and Shenzhen fluctuated upwards in the first half of the day, with bank stocks steadily rising

AASTOCKS·
SH
601398
+0.28%
HK
01398
-1.16%
SH
688520
+1.31%
AASTOCKS·
SH
601398
+0.28%
HK
01398
-1.16%
SH
688520
+1.31%

Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-ups

Zhitong·
SZ
300485
-5.49%
SH
603716
-1.20%
SH
688520
+1.31%
Zhitong·
SZ
300485
-5.49%
SH
603716
-1.20%
SH
688520
+1.31%

Sinocelltech's subsidiary product SCTB39G has received the drug clinical trial approval notice

Zhitong·
SH
688520
+1.31%
Zhitong·
SH
688520
+1.31%

Sinocelltech's subsidiary product SCTB39-1 has received approval for clinical drug trials

Zhitong·
SH
688520
+1.31%
Zhitong·
SH
688520
+1.31%

Overview of CAR-T therapy concept stocks with the highest increase in trading volume

Zhitong·
SZ
000566
-2.51%
SH
688520
+1.31%
SZ
300181
+0.35%
Zhitong·
SZ
000566
-2.51%
SH
688520
+1.31%
SZ
300181
+0.35%
© 2026 Longbridge｜Disclaimer